Clinical trial
Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults
NCT04863131 is registered in ClinicalTrials.gov with Fujita Health University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Immunogenicity of Intradermal SARS-CoV-2 Vaccine EXG-5003 in Healthy Adults
- Lead sponsor
- Fujita Health University
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- April 28, 2021
- Completion date
- January 24, 2023
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.